Presented today at #ENDO2023: In the TRAVERSE study, a randomized trial involving men with hypogonadism and preexisting or a risk of cardiovascular disease, testosterone therapy was noninferior to placebo with respect to major adverse cardiac events. nej.md/3Ja6c4N